Declan G. Murphy

Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.

BACKGROUND: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is reshaping nodal staging in prostate cancer by detecting regional lymph node metastases with greater accuracy than conventional imaging. This has created a new cohort of patients with N1M0 di...

Effect of the November 2023 Medicare Benefits Schedule PSA Testing Reform on National Utilisation, Diagnostic Activity, and Health-System Expenditure in Australia

Background/Objectives: On 1 November 2023, the Medicare Benefits Schedule (MBS) introduced major reforms to prostate-specific antigen (PSA) testing in Australia, extending the minimum re-test interval for average-risk men (item 66655) from 12 to 23 months and introducing a new an...